Compare Gilead Sciences, Inc. (GILD) vs Stanley Black & Decker, Inc. (SWK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gilead Sciences, Inc. vs Stanley Black & Decker, Inc. — how do they compare? Gilead Sciences, Inc. trades at $134.78 (market cap $163.51B), while Stanley Black & Decker, Inc. trades at $90.11 (market cap $13.67B). The key difference: Gilead Sciences, Inc. is far larger — about 12× Stanley Black & Decker, Inc.'s market cap, and Stanley Black & Decker, Inc. pays the higher dividend (3.77%). Which is the better fit depends on your goals.
| GILD | SWK | |
|---|---|---|
Market Cap | $163.51B | $13.67B |
Sector | Health | — |
52-Week High | $155.80 | $94.12 |
52-Week Low | $108.22 | $62.12 |
Enterprise Value | $178.05B | $19.84B |
Dividend Yield | 2.49% | 3.77% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Stanley Black & Decker (SWK) trades at $90.11, up 3.14% today, with a neutral technical signal and bullish moving averages. The company has beaten earnings estimates for three consecutive quarters, with Q2 2026 results pending. Revenue trends show stability around $15B annually, while net income improved to $402M in 2025. Valuation metrics include a P/E of 36.05 and P/S of 0.88, with a dividend payout scheduled for June 2026.
SWK offers a turnaround story with earnings beats and cost-saving efforts, but faces headwinds from weak Tools & Outdoor demand and high debt. Analyst consensus is mixed with 43% buy ratings, a $82.75 price target below current levels, and risks including consumer sentiment and interest rate sensitivity. The stock's near-term direction hinges on Q2 earnings due July 29, 2026.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →About Stanley Black & Decker, Inc.
Stanley Black & Decker Inc is a manufacturer of hand and power tools. The company operates three business segments: tools and storage, security, and industrial. Tools and storage, the largest segment by revenue, sells hand tools and power tools to professional end-users, distributors, retail consumers, and industrial customers. Security installs electronic security systems and provides electronic security services including alarm monitoring and video surveillance. Industrial sells engineered fastening products such as stud-welding systems, blind inserts and tools, and engineered plastic and mechanical fasteners. The largest end market is the United States of America.
Read more on SWK →
